Nicox has appointed Gavin Spencer as Chief Executive Officer.
Nicox has appointed Gavin Spencer as Chief Executive Officer.
The appointment has immediate effect, following the Board’s decision to end the mandate of Andreas Segerros.
Gavin was most recently Executive Vice-President, Chief Business Officer & Head of Corporate Development at Nicox. He has spent more than 25 years in the life sciences industry and combines strong business acumen with a solid scientific background and broad strategic, financial, corporate development, commercial and operational management experience in biotechs and large pharma. During his time with Nicox, since 2005, Gavin Spencer has had a key role in building and managing Nicox’s partnerships, including closing agreements with Pfizer, Bausch + Lomb, VISUfarma and Ocumension Therapeutics.
He has also been involved in equity raising and investor relations at Nicox for many years and has led the Company’s recent financing activities.
Source link
#Gavin #Spencer #PharmaTimes
